Can Celestica's Next-Generation HealthTech Portfolio Lift Its Shares?

Celestica Inc. CLS plays a key role in the healthcare technology sector by providing advanced manufacturing, engineering and supply chain solutions to medical device companies. Its expertise in diagnostics, surgical technologies, patient monitoring and other healthcare applications helps customers bring sophisticated medical products to market.

Celestica’s HealthTech manufacturing portfolio includes medical imaging systems, surgical equipment, diabetes-care devices, in-vitro diagnostic instruments and connected medical products. It provides services such as design and development, precision manufacturing, systems integration and after-market support, helping customers improve product quality, reduce costs and meet regulatory requirements.

The company also uses its global manufacturing footprint and supply chain capabilities to manage complex production needs, improving efficiency, enhancing reliability and supporting the production of highly regulated medical devices. Celestica works with healthcare and medical technology companies across the product lifecycle, from initial development through large-scale manufacturing and ongoing support.

As adoption of digital health solutions, smart medical devices, surgical robotics and advanced diagnostic equipment continues to increase, Celestica is well positioned to benefit from the expanding HealthTech market.

How Are Competitors Advancing in the HealthTech Market?

Celestica faces competition from Jabil, Inc. JBL and Sanmina Corporation SANM. Jabil has a broad HealthTech business that supports the development and manufacturing of medical devices and healthcare products. The company is focusing on areas such as connected health, diagnostics, medical equipment and drug-delivery technologies. Jabil’s manufacturing and supply-chain capabilities are helping healthcare companies bring new products to market more efficiently.

Sanmina has a strong presence in HealthTech, providing specialized solutions for medical device manufacturers. Its capabilities span areas such as cardiovascular care, robotic surgery and patient monitoring. Sanmina combines engineering, manufacturing and supply-chain services to support the development and production of medical technologies.

Celestica's Price Performance, Valuation & Estimates

Celestica shares have soared 39.1% over the past year compared with the industry’s growth of 50.1%.

Image Source: Zacks Investment Research

From a valuation standpoint, Celestica trades at a forward price-to-earnings ratio of 20.71, up from the industry average of 19.66.

Image Source: Zacks Investment Research

Earnings estimates for 2026 have increased 11.4% to $11.32 per share over the past 60 days, while the same for 2027 has increased 30.2% to $19.01.

Image Source: Zacks Investment Research

Celestica currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research